MYOK News and Press, MyoKardia Inc. From 10/29/20

MYOK may have seemed an expensive and unwanted use of cash at first, but it couldn't have been too bad for management to have bought it. Indeed, successfully raising clinical awareness for HCM and R&D successes will have made the acquisition a good bargain. We can determine th...

NEW YORK, NY / ACCESSWIRE / October 24, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating: Standard AVB Financial Corp. (NASDAQ:STND) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to...

NEW YORK, NY / ACCESSWIRE / October 21, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating: MyoKardia, Inc. (NASDAQ:MYOK) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Bristol-Mye...

NEW YORK, NY / ACCESSWIRE / October 21, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating: MobileIron, Inc. (NASDAQ:MOBL) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Ivanti, I...

NEW YORK, NY / ACCESSWIRE / October 20, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Eidos Therapeutics, Inc. (NASDAQ: EIDX ) rela...

As the pandemic resurges, early vaccine trials are reaching the home stretch. Vaccine results now pushed back to mid-to-late November at the earliest, and there have been delays in therapeutic treatments. Healthcare overall has been burdened by the uncertainty on the Affordable Ca...

NEW YORK, NY / ACCESSWIRE / October 13, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating: MyoKardia, Inc. (NASDAQ:MYOK) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Bristol-Myers ...

Merger activity decreased last week with four new deals announced. The acquisition of MyoKardia by Bristol Myers Squibb Company. The acquisition of Eaton Vance by Morgan Stanley. For further details see: Merger Arbitrage Mondays - Bristol Myers Squibb...

Shares of relatively unknown biotech company MyoKardia (NASDAQ: MYOK) jumped overnight after Bristol Myers Squibb (NYSE: BMY) agreed to pay a steep premium to acquire the clinical-stage biotech and its pipeline of cardiovascular drugs. Over the past several years, we've ...

Bristol Myers Squibb is making a big $13-billion deal, less than a year after the Celgene acquisition closed. That purchase is delivering according to, and even exceeding, expectations. While the situation looked quite reasonable, I feel that the latest purchase is a bit too rushe...